Cormorant Asset Management, LP Aclaris Therapeutics, Inc. Transaction History

Cormorant Asset Management, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$9.74 - $17.92 $8.77 Million - $16.1 Million	-900,000 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$12.27 - $18.49 $7.36 Million - $11.1 Million	-600,000 Reduced 40.0%	900,000 $13.1 Million
Q3 2021 Nov 15, 2021	SELL	$13.38 - $18.8 $6.69 Million - $9.4 Million	-500,000 Reduced 25.0%	1,500,000 $27 Million
Q1 2021 May 17, 2021	BUY	$5.86 - $27.73 $11.7 Million - $55.5 Million	2,000,000 New	2,000,000 $50.4 Million
Q4 2019 Feb 14, 2020	SELL	$1.02 - $1.97 $255,000 - $492,500	-250,000 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$2.13 - $7.06 $363,282 - $1.2 Million	-170,555 Reduced 40.55%	250,000 $548,000
Q1 2019 May 15, 2019	SELL	$5.63 - $7.84 $323,725 - $450,800	-57,500 Reduced 12.03%	420,555 $2.52 Million
Q4 2018 Feb 14, 2019	SELL	$6.3 - $15.4 $138,253 - $337,953	-21,945 Reduced 4.39%	478,055 $3.53 Million
Q3 2018 Nov 14, 2018	SELL	$14.38 - $20.89 $367,236 - $533,488	-25,538 Reduced 4.86%	500,000 $7.26 Million
Q1 2018 May 15, 2018	SELL	$17.08 - $25.64 $417,810 - $627,205	-24,462 Reduced 4.45%	525,538 $9.21 Million
Q3 2017 Nov 14, 2017	BUY	$23.02 - $28.8 $12.7 Million - $15.8 Million	550,000	550,000 $14.2 Million

50.7M

30.6K

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $137M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.